Hawkins Richard J

Director Hawkins bought 48,225 shares of SVRA at $2.04; holdings up 71.7% to 115,466 shares. Company unprofitable with $-26.6M net income.

Director Richard J Hawkins purchased 48,225 shares at $2.04 on 2025-06-20, increasing his holdings by 71.7% from 67,241 to 115,466 shares at a total cost of $98,571.90. His cross-ticker track record shows 3 prior open-market buys with an average 90-day return of +2415.9% and a 100.00% win rate across all holdings, establishing a strong pattern of successful buy-side timing. However, this transaction occurs against a deteriorating backdrop: Savara Inc reported zero revenue in the latest quarter and a full-year net income of $-26,639,000.00 on a $373,327,751.52 market cap, indicating persistent unprofitability. The current price of $2.16 is 57.4% below the 52-week high and down 23.9% over the past 30 days, placing the trade well below recent valuations. While the director's prior success across other equities demonstrates analytical acumen, the concentrated purchase during ongoing fundamental weakness at Savara warrants examination of whether this represents conviction in a turnaround or a timing signal that contradicts broader market deterioration.

Director Hawkins buys 4,000 PSTV shares at $1.50; 4 other insiders bought within 14 days as cluster activity.

Richard J Hawkins, a director of PLUS THERAPEUTICS, purchased 4,000 shares at $1.50 on 2024-09-13, increasing his holdings by 35.8% to 15,188 shares post-transaction. This buy occurs within a cluster pattern: 4 other insiders also acquired shares within the past 14 days, suggesting coordinated or independently-motivated director-level confidence. At the transaction price of $1.50, the stock was significantly depressed—currently trading at $39.75, a 2,550% appreciation from the buy price. Notably, Hawkins' prior trade at PSTV on 2024-05-08 (a buy at $1.50 equivalent value) achieved a 90-day return of +1860.8%, while his cross-ticker track record across 2 prior buys shows a 100% win rate with an average 90-day return of +1860.8%, indicating a strong historical pattern of well-timed accumulation. However, the company remains unprofitable with a net loss of $-2.9M in the latest quarter, though annual revenue growth stands at +36.5%, creating a contrasting fundamental picture of operational losses alongside revenue expansion.

Director Hawkins buys 6,285 shares of PSTV at $1.35; holdings surge to 11,188 shares; 4 other insiders bought in past 14 days

Hawkins Richard J (Director) purchased 6,285 shares at $1.35, increasing his position from 4,903 to 11,188 shares, a 128.2% increase. This transaction is part of a cluster pattern in which 4 other insiders also bought within the past 14 days, suggesting coordinated or simultaneous board interest. His cross-ticker track record shows strong past performance (2 prior buys with 100.00% 90-day win rate), and his prior PSTV purchase on 2024-05-08 delivered +1860.8% over 90 days. However, the current fundamental picture is mixed: PLUS THERAPEUTICS generated only $703.0K in quarterly revenue, remains unprofitable with $-2.9M net income, and the stock is currently -42.6% from its 52-week high despite +11.0% 30-day momentum. The multi-insider buying activity and insider's favorable historical timing merit investor attention to the company's operational trajectory.